A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

Launched by IMPERIAL COLLEGE LONDON · Apr 9, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether infections caused by the common cold can worsen symptoms in adults with bronchiectasis, a condition that affects the lungs. Researchers want to see how these viral infections impact individuals with bronchiectasis compared to healthy volunteers. Participants will undergo some initial tests to determine if they qualify for the study, and if they do, they will receive a nasal spray containing a virus that causes the common cold. Over the next six weeks, they will have regular check-ups where they will share their symptoms and undergo various tests to monitor their lung function and immune response.

To be eligible, healthy volunteers need to be between 18 and 65 years old, while participants with bronchiectasis must have a confirmed diagnosis of the condition and meet specific severity criteria. Those selected will be closely monitored throughout the study, providing valuable information about how viral infections might affect people with bronchiectasis. It’s important for potential participants to be aware that certain health conditions or recent treatments may disqualify them from joining the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * For healthy volunteers:
• • 1) Age 18 to 65 years.
• * For bronchiectasis study subjects:
• • 1. Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .
• • 2. For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.
• Exclusion Criteria:
• * For healthy volunteers and bronchiectasis study subjects:
• • 1. Any medical co-morbidity impacting the study in the opinion of the medical team
• • 2. Current smoking history within last 12 months or ex smoking history \>5 pack years
• • 3. Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)
• • 4. Close contact with infants or elderly individuals either at home or workplace
• • 5. Pregnancy or breastfeeding
• * For bronchiectasis study subjects:
• • 1) Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with other significant chronic lung disease diagnoses (eg. interstitial lung disease) which would impact the study in the opinion of the medical team 4) FEV1 \< 50% predicted 8) Recent antibiotics for exacerbations within the preceding 6 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks.